250 reports of this reaction
2.2% of all POTASSIUM IODIDE reports
#4 most reported adverse reaction
HAEMORRHAGIC STROKE is the #4 most commonly reported adverse reaction for POTASSIUM IODIDE, manufactured by Avondale Pharmaceuticals, LLC. There are 250 FDA adverse event reports linking POTASSIUM IODIDE to HAEMORRHAGIC STROKE. This represents approximately 2.2% of all 11,184 adverse event reports for this drug.
Patients taking POTASSIUM IODIDE who experience haemorrhagic stroke should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGIC STROKE is a less commonly reported adverse event for POTASSIUM IODIDE, but still significant enough to appear in the safety profile.
In addition to haemorrhagic stroke, the following adverse reactions have been reported for POTASSIUM IODIDE:
The following drugs have also been linked to haemorrhagic stroke in FDA adverse event reports:
HAEMORRHAGIC STROKE has been reported as an adverse event in 250 FDA reports for POTASSIUM IODIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGIC STROKE accounts for approximately 2.2% of all adverse event reports for POTASSIUM IODIDE, making it a notable side effect.
If you experience haemorrhagic stroke while taking POTASSIUM IODIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.